APL-2401 (ASN-8639)
FGFR2/3-Driven Advanced Solid Tumors
Phase 1First Patient Dosed (China)
Key Facts
Indication
FGFR2/3-Driven Advanced Solid Tumors
Phase
Phase 1
Status
First Patient Dosed (China)
Company
About Asieris Pharmaceuticals
Founded in 2010 and publicly listed in China (688176.SH), Asieris Pharmaceuticals is a global biopharma leader in genitourinary and women's health. Its strategy integrates in-house R&D with global partnerships, supported by advanced technology platforms for drug discovery. The company has achieved significant milestones, including the approval of its first-in-class therapy Cevira® in China and the submission of a Marketing Authorization Application to the European Medicines Agency.
View full company profile